Overall, our data indicate that eIF4G1 may function as an oncoprotein in PCa and serve as a new diagnostic and/or prognostic marker in PCa, and a potential therapeutic target for intervention in CRPC (Fig. 7). Here, EIF4G1 is linked to posterior cortical atrophy.